Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 14Gastrointestinal 7Sarcoma 2Head & Neck 2Genitourinary 2Tumor-Agnostic 1Endocrine 1Breast 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Osteosarcoma 1Osteonecrosis 1Osteomyelitis 1Chondrosarcoma 1Bone Neoplasms 1

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Ferrosoferric Oxide × Sarcoma × Clear all
NCT01336803 2023-12-27

Osteosarcoma

Stanford University

Phase 2 Completed
32 enrolled 11 charts
Sarcoma

Bone Neoplasms, Chondrosarcoma, Osteomyelitis, Osteonecrosis, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

NCT01663090 2020-10-19

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Dana-Farber Cancer Institute

Phase NA Withdrawn
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡